viropharma inc (VPHM:NASDAQ GS)

Executive Profile*

Background*

Dr. Claude H. Nash Ph.D. served as the Chief Executive Officer of Accera, Inc. Dr. Nash served as the Chief Executive Officer of ViroPharma Inc. and President from 1994 to 2002. Dr. Nash has more than 30 years of pharmaceutical industry experience, which includes advancing more than 20 compounds into clinical trials, five of which are approved products. Dr. Nash co-founded ViroPharma Inc., and served as its Executive Officer until August 2004. He served as the Chief ... Executive of Bloodstone from August 2007 to December 2007. From 2004 to 2006, he served as a Vice President of Research and Development at the University of Maryland Biotechnology Institute. From 1983 to 1994, Dr. Nash served as a Vice President of Infectious Disease and Tumor Biology at Schering-Plough Research Institute. He served as the Head of Infectious Disease at SmithKline Beecham. He serves as Executive Chairman of SelectX Pharmaceuticals, Inc. Dr. Nash serves as the Chairman of the Board of Accera, Inc. and Bloodstone Ventures, plc. Dr. Nash served as the Chairman of Bloodstone from August 2007 to December 2007 and ViroPharma from February 1997 to September 2000. He has been a Director of Adolor Corporation, since January 2000. He serves as an Independent Director at SelectX Pharmaceuticals, Inc. Dr. Nash serves as a Director of NoCopy Inc. He serves as a Member of Advisory Board of Physicians Clinical Research Solutions, Inc. He serves as a Trustee of The Burnham Institute. Dr. Nash served as a Director of Nocopi Technologies Inc. from August 2002 to September 24, 2004. He served as a Director of ViroPharma Inc. since December 1994 until 2000. He is a Member of The American Academy of Microbiology, Phi Kappa Phi, Sigma Xi and Beta, Beta, Beta, Biological honor societies. He received the Charles Porter Award from the Society for Industrial Microbiology. Dr. Nash has a B.S. in Biology and Chemistry from Lamar University, an M.S. in Microbiology and a Ph.D. in Microbial Genetics and Biochemistry from Colorado State University.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
VPHM:US	$27.04 USD	+0.60

COMPETITOR COMPENSATION